Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Non-Current Assets (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Non-Current Assets for 6 consecutive years, with $26.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 45.74% to $26.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $136.5 million through Dec 2025, down 30.52% year-over-year, with the annual reading at $26.5 million for FY2025, 45.74% down from the prior year.
  • Non-Current Assets hit $26.5 million in Q4 2025 for Bolt Biotherapeutics, down from $29.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $118.6 million in Q4 2021 to a low of $26.5 million in Q4 2025.
  • Historically, Non-Current Assets has averaged $62.2 million across 5 years, with a median of $53.8 million in 2021.
  • Biggest five-year swings in Non-Current Assets: surged 459.74% in 2021 and later tumbled 53.56% in 2022.
  • Year by year, Non-Current Assets stood at $118.6 million in 2021, then crashed by 53.56% to $55.1 million in 2022, then decreased by 1.79% to $54.1 million in 2023, then fell by 9.72% to $48.8 million in 2024, then tumbled by 45.74% to $26.5 million in 2025.
  • Business Quant data shows Non-Current Assets for BOLT at $26.5 million in Q4 2025, $29.4 million in Q3 2025, and $37.2 million in Q2 2025.